Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice

Table 1 Demographic, clinical and immunological fetures of study subjects

Age (y)	Patients	Systemic event	Local event	Baseline challenge ( +)
6–18:	45	35	10	6
19–39:	17	14	3	11
40–65:	4	4		–
Total:	66	53 (80%)	13 (20%)	17 (25%)

Sex
Female:	45 (68%)
Male:	21 (32%)

	Systemic event	Local event	Baseline challenge ( +)
sIgE range (kU/L)
0.11–4.9:	3	2	2
5–19.9:	11	6	6
20–59.9:	21	4	6
60–99.9:	10	1	3
100–299.9:	5	–	–
> 300:	3	–	–
sIgE percent of total IgE
0.1–0.9%:	–	–	–
1–2.9%:	–	2	–
3–4.9%:	2	5	2
5–9.9%:	6	2	5
10–19%:	24	1	6
20–40%:	12	3	4
> 40%:	9	-	–
Shrimp skin test vs. Histamine
0.6x–1x:	12	6	6
1.1x–2x:	19	3	8
> 2x:	22	4	3

Age: age at the time of review
Systemic Event: number of subjects whose presentation was with a history of systemic reaction upon exposure
Local Event: number of subjects whose presentation was with a history of isolated symptom, or combination of symptoms from different systems whose localized nature and limited extent would not have required use of epinephrine
Baseline Challenge ( +): number of subjects in whom diagnosis of shrimp allergy with manifestations of systemic nature confirmed by oral challenge prior to initiation of sublingual immunotherapy
sIgE range: baseline sIgE on presentation. Samples that yielded values > 100 kU/L were diluted 1:10, re-tested, and the resulting concentration was corrected for 1:10 dilution
sIgE percent of total IgE: Shrimp IgE expressed as a percentage of Total IgE
Skin Test vs. Histamine: size of Shrimp skin prick test reaction (wheal’s maximal diameter) compared to Histamine control

ISSN: 1710-1492